Related Experiment Video
Updated: Oct 2, 2025
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Mycophenolate versus Methotrexate in Non-infectious Ocular Inflammatory Disease: A Systematic Review and
Mohammad Karam1,2, Abdulmalik Alsaif1,3, Abdulrahman Al-Naseem4
1Bachelor of Medicine and Bachelor of Surgery (MBChB), School of Medicine, University of Leeds, Leeds, UK.
Purpose:
To compare the outcomes of mycophenolate mofetil (MMF) versus methotrexate (MTX) in non-infectious ocular inflammatory disease (NIOID).
Methods:
The study was performed as per the PRISMA Guidelines. A search identified all studies comparing MMF versus MTX in NIOID. Treatment result and side effects were primary outcomes.
Results:
Four studies enrolling 905 patients were identified. There was no significant difference between MMF and MTX groups in overall treatment success (OR = 0.97, P = .96), treatment failure (OR = 0.86, P = .85). MTX showed a significantly improved effect in cases involving posterior uveitis and panuveitis (OR = 0.41, P = .003). In addition, MTX was associated with a faster median time to treatment success and had less side effects when compared to MTX, however this was not significant. For secondary outcomes, no significant difference was found in visual acuity and resolution of macular oedema.
Conclusion:
MMF is comparable to MTX in the treatment of NIOID.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...